Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Type I interferons (IFN-I) are critical for antiviral immunity; however, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections. We demonstrated in mice that blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T cells and was associated with enhanced IFN-γ production. Thus, we demonstrated that interfering with chronic IFN-I signaling during persistent infection redirects the immune environment to enable control of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 933
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationInterferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Resolution of a chronic viral infection after interleukin-10 receptor blockade
Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., & von Herrath, M. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061462 · Cited by 548
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.-S., Kunkel, D., Petitjean, G., Dillies, M.-A., Roques, P., Butor, C., Silvestri, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40093 · Cited by 481
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Pathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Research works printed but not linked: 2
- Brockman MA Blood 2009 114 346 19365081 PMC2714209 · DOI · Paper page
- 10.1089/jir.2012.0037 · DOI
Cited by
Items 301–400 of 713
Lemos, H., Huang, L., McGaha, T. L., & Mellor, A. L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344407 · Cited by 35
Effects of type I interferons in malaria
Sebina, I., & Haque, A. (2018) · Immunology · doi:10.1111/imm.12971 · Cited by 42
Eshleman, E. M., & Lenz, L. L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00431 · Cited by 42
“Type I IFNs were also associated with the induction of IL-10 secretion and Programed death-ligand 1 (PD-L1) expression by myeloid cells during chronic LCMV infection (109, 110).”
BackgroundResultInfluentialDivergent effects of type-I interferons on regulatory T cells
Piconese, S., Pacella, I., Timperi, E., & Barnaba, V. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.10.012 · Cited by 39
“Such chronic IFN signaling has been recently recognized as detrimental in a mouse model of chronic LCMV infection, by establishing an immunosuppressive program through the involvement of IL-10- and PD-L1-mediated signals in effector T cells [63,64].”
Li, G., Zhao, J., Cheng, L., Jiang, Q., Kan, S., Qin, E., Tu, B., Zhang, X., Zhang, L., Su, L., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006505 · Cited by 37
T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases
McKinney, E. F., & Smith, K. G. (2016) · Immunology & Cell Biology · doi:10.1038/icb.2016.81 · Cited by 36
Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury
Hackstein, C.-P., Spitzer, J., Symeonidis, K., Horvatic, H., Bedke, T., Steglich, B., Klein, S., Assmus, L. M., Odainic, A., Szlapa, J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.026 · Cited by 39
IFN-λ Exerts Opposing Effects on T Cell Responses Depending on the Chronicity of the Virus Infection
Misumi, I., & Whitmire, J. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301705 · Cited by 38
Gibb, D. R., Liu, J., Santhanakrishnan, M., Natarajan, P., Madrid, D. J., Patel, S. R., Eisenbarth, S. C., Tormey, C. A., Stowell, S. R., Iwasaki, A., et al. (2017) · Transfusion · doi:10.1111/trf.14288 · Cited by 36
Oh, J. H., Kim, M. J., Choi, S. J., Ban, Y. H., Lee, H. K., Shin, E., Lee, K.-M., & Ha, S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0403 · Cited by 37
“Although levels decline in the later phases of chronic infection due to numerous negative regulators (30), studies have shown that residual type I IFNs play an important role in preventing excessive T-cell activation LCMVmouse models (10, 11).”
BackgroundContext Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease
Fox, L. E., Locke, M. C., & Lenschow, D. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606874 · Cited by 40
“org 5 negative immune regulators IL-10 and programmed deathligand 1 (PD-L1), increased protective adaptive immune responses, and accelerated clearance of persistent virus (78, 79, 105).”
BackgroundA sustained type I IFN-neutrophil-IL-18 axis drives pathology during mucosal viral infection
Lebratti, T. J., Lim, Y. S., Cofie, A., Andhey, P. S., Jiang, X., Scott, J. M., Fabbrizi, M. R., Ozantürk, A. N., Pham, C. T. N., Clemens, R. A., et al. (2021) · eLife · doi:10.7554/elife.65762 · Cited by 36
Rappe, J. C. F., Finsterbusch, K., Crotta, S., Mack, M., Priestnall, S. L., & Wack, A. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201631 · Cited by 39
“For instance, strong IFN responses and CS have been described for primates infected with a highly pathogenic influenza virus (Baskin et al., 2015; Wilson et al., 2013).”
BackgroundJung, I.-Y., Bartoszek, R. L., Rech, A. J., Collins, S. M., Ooi, S., Williams, E. F., Hopkins, C. R., Narayan, V., Haas, N. B., Frey, N. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1175 · Cited by 39
Early Virus-Host Interactions Dictate the Course of a Persistent Infection
Sullivan, B. M., Teijaro, J. R., de la Torre, J. C., & Oldstone, M. B. A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004588 · Cited by 37
“Notably, we [18] and others [19] have recently reported that, unexpectedly, IFN-I induced early during infection of mice with the immunosuppressive strain clone 13 (Cl13) of LCMV plays a critical role in the establishment of Cl13 persistence.”
BackgroundThe interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?
Deeks, S. G., Odorizzi, P. M., & Sékaly, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci91916 · Cited by 36
“In this model, long-term viral control is mediated by decreased immune activation, decreased PD-1/PD-L1 activity, restored lymphoid architecture, and improved CD4+ T cell function (16, 17).”
BackgroundProtozoan parasites and type I interferons: a cold case reopened
Beiting, D. P. (2014) · Trends in Parasitology · doi:10.1016/j.pt.2014.07.007 · Cited by 39
Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8+ T Cell Responses
Dickow, J., Francois, S., Kaiserling, R.-L., Malyshkina, A., Drexler, I., Westendorf, A. M., Lang, K. S., Santiago, M. L., Dittmer, U., & Sutter, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02255 · Cited by 39
Sato, T., Ishikawa, S., Asano, J., Yamamoto, H., Fujii, M., Sato, T., Yamamoto, K., Kitagaki, K., Akashi, T., Okamoto, R., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0545-5 · Cited by 35
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense
Wang, L., & Ning, S. (2021) · Viruses · doi:10.3390/v13020279 · Cited by 37
Künzli, M., Reuther, P., Pinschewer, D. D., & King, C. G. (2021) · eLife · doi:10.7554/elife.61869 · Cited by 37
“infection rescues the Th1 effector compartment and improves viral control, although 215 this likely depends on the rate of viral replication(55-57).”
BackgroundPadmanabhan, P., Garaigorta, U., & Dixit, N. M. (2014) · Nature Communications · doi:10.1038/ncomms4872 · Cited by 37
Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo
Abdel‐Mohsen, M., Deng, X., Liegler, T. J., Guatelli, J., Salama, M., Ghanem, H. E.-D. A., Rauch, A., Ledergerber, B., Deeks, S. G., Günthard, H. F., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02687-13 · Cited by 35
“infection suggest that IFN- is associated with both beneficial and detrimental disease outcomes and that the overall balance between the various, diverse effects of type I interferon ultimately determines the course of disease (14, 15).”
BackgroundKharel, A., Shen, J., Brown, R. J., Chen, Y., Nguyen, C. P., Alson, D., Bluemn, T., Fan, J., Gai, K., Zhang, B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112649 · Cited by 35
“Additionally, a cluster containing STAT1 and STAT2 (motif accessibility heatmap cluster 4), which are both known TFs involved in IFN-I response, 58,60,61 showed enriched accessibility in the progenitor subset (Figure 6A).”
BackgroundGuéry, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729233 · Cited by 34
“Here, blockade of IFN-I signaling even during the acute phase of infection facilitated a long-term viral clearance (56, 57).”
BackgroundComplex Regulation Pattern of IRF3 Activation Revealed by a Novel Dimerization Reporter System
Wang, Z., Ji, J., Peng, D., Ma, F., Cheng, G., & Qin, F. X.-F. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502458 · Cited by 35
“Chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent lymphocytic choriomeningitis virus infections (10, 12).”
BackgroundSelf-citationLocke, M. C., Fox, L. E., Dunlap, B. F., Young, A. R., Monte, K. J., & Lenschow, D. J. (2021) · Journal of Virology · doi:10.1128/jvi.01143-21 · Cited by 33
Xing, J., Chai, Z., Ly, H., & Liang, Y. (2015) · Journal of Virology · doi:10.1128/jvi.01674-15 · Cited by 33
Wang, X., Caffrey-Carr, A. K., Liu, K.-W., Espinosa, V., Croteau, W., Dhingra, S., Rivera, A., Cramer, R. A., & Obar, J. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000802 · Cited by 34
MZB1 enables efficient interferon α secretion in stimulated plasmacytoid dendritic cells
Kapoor, T., Corrado, M., Pearce, E. L., Pearce, E. J., & Grosschedl, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-78293-3 · Cited by 33
Immunosurveillance encounters cancer metabolism
Chuang, Y., Tzeng, S., Ho, P., & Tsai, C. (2024) · EMBO Reports · doi:10.1038/s44319-023-00038-w · Cited by 34
“…chromatin accessibility, while abrogating Type I IFN or IFN γ signaling in tumor cells improves the function of many immune compartments, such as CD8 + T cells, NK cells, and innate lymphoid cells (Benci et al, 2019; Benci et al, 2016; Qiu et al, 2023; Teijaro et al, 2013; Wilson et al, 2013).”
BackgroundTLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral Infection
Hotz, C., Roetzer, L. C., Huber, T., Sailer, A. W., Oberson, A., Treinies, M., Heidegger, S. M., Herbst, T., Endres, S., & Bourquin, C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500079 · Cited by 33
“Additionally, excessive or prolonged type I IFN release and RLR stimulation can have immunopathological (38–41) or immunosuppressive (42, 43) effects, underscoring the need for tight control of this cytokine.”
BackgroundGiles, E. M., Sanders, T. J., McCarthy, N. E., Lung, J., Pathak, M., MacDonald, T. T., Lindsay, J., & Stagg, A. J. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.44 · Cited by 35
George, J., & Mattapallil, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00299 · Cited by 33
“On the other hand, blockade of chronic IFN signaling was shown to decrease immune activation and clear persistent LCMV infection in mice (55).”
BackgroundMoinuddin, A., Poznanski, S. M., Portillo, A. L., Monteiro, J. K., & Ashkar, A. A. (2024) · Immunological Reviews · doi:10.1111/imr.13316 · Cited by 34
“133 However, when the viral infection is not resolved, IFN signaling persists and suppresses innate immune antiviral responses.”
BackgroundDown regulation of macrophage IFNGR1 exacerbates systemic L. monocytogenes infection
Eshleman, E. M., Delgado, C., Kearney, S. J., Friedman, R. S., & Lenz, L. L. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006388 · Cited by 33
Exhaustion and Inflation at Antipodes of T Cell Responses to Chronic Virus Infection
Čičin‐Šain, L., & Arens, R. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.11.012 · Cited by 32
Guo, K., Shen, G., Kibbie, J. J., González, T., Dillon, S. M., Smith, H., Cooper, E., Lavender, K. J., Hasenkrug, K. J., Sutter, K., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008986 · Cited by 33
Mitochondrial RNA , a new trigger of the innate immune system
Grochowska, J., Czerwińska, J., Borowski, L. S., & Szczęsny, R. J. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1690 · Cited by 33
“, 2021), and (c) chronic viral (lymphocytic choriomeningitis virus and HIV) (Sugawara et al., 2019; Wilson et al., 2013) or mycobacterial (Mycobacterium tuberculosis and Mycobacterium leprae) infections (Berry et al.”
BackgroundB cell–derived IL-27 promotes control of persistent LCMV infection
Pratumchai, I., Žák, J., Huang, Z., Min, B., Oldstone, M. B. A., & Teijaro, J. R. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116741119 · Cited by 33
Koma, T., Huang, C., Kolokoltsova, O. A., Brasier, A. R., & Paessler, S. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.09.028 · Cited by 33
Type 1 Interferon in the Human Intestine—A Co-ordinator of the Immune Response to the Microbiota
Giles, E. M., & Stagg, A. J. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001078 · Cited by 33
Wang, B., Kang, W., Zuo, J., 康文臻, & Sun, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01431 · Cited by 36
“This subset skewing likely contributes to the progressive IFN-I-mediated immune dysregulation (61, 89).”
BackgroundLack of Ikaros Deregulates Inflammatory Gene Programs in T Cells
Ana, C. L. D., Arakcheeva, K., Agnihotri, P., Derosia, N. M., & Winandy, S. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801270 · Cited by 32
de, M. M., Good, M. F., McCarthy, J. S., & Engwerda, C. R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600619 · Cited by 34
“They are required for antiviral defenses, but can also promote pathogen survival by suppressing immunity during infections, such as those caused by lymphocytic choriomeningitis virus (122, 123), influenza (124), Mycobacteria (125–129), Listeria (130), Staphylococci (131), Leishmania (132) and Plasmodium (133, 134).”
BackgroundClouthier, D., Zhou, A. C., & Watts, T. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401002 · Cited by 33
“it appears that LCMV-infected cells have lower levels of GITRL, although concomitantly upregulating PD-L1, the latter finding having previously been reported (28, 29).”
BackgroundResultZeng, Z., Li, L., Chen, Y., Wei, H., Sun, R., & Tian, Z. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151218 · Cited by 32
“Recent studies indicate that chronic lymphocytic choriomeningitis virus infection can redirect IFN-α/β to induce negative immunity to support viral persistence instead of clearance (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundSmith, J. A., Mathew, L., Gaikwad, A., Rech, B., Burney, M., Faro, J. P., Lucci, J. A., Bai, Y., Olsen, R. J., & Byrd, T. T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00173 · Cited by 31
Future Therapy for Hepatitis B Virus: Role of Immunomodulators
Pham, E. A., Perumpail, R. B., Fram, B. J., Glenn, J. S., Ahmed, A., & Gish, R. G. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0315-9 · Cited by 31
Abdel-Hakeem, M. S. (2019) · Viruses · doi:10.3390/v11020106 · Cited by 32
“In chronic infection, there is a persistent elevated level of IFN-I in many contexts, and blocking IFN-I signaling enhances viral control [119,120].”
BackgroundSphingosine kinase 2 restricts T cell immunopathology but permits viral persistence
Studstill, C. J., Pritzl, C. J., Seo, Y., Kim, D. Y., Xia, C., Wolf, J. J., Nistala, R., Vijayan, M., Cho, Y., Kang, K. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci125297 · Cited by 30
AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections
Smith, J. A., Gaikwad, A., Mathew, L., Rech, B., Faro, J. P., Lucci, J. A., Bai, Y., Olsen, R. J., & Byrd, T. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.881902 · Cited by 30
“org 6 This reset of the host immunity was demonstrated in two independent studies by Wilson and colleagues and Teijaro and colleagues, who evaluated lymphocytic choriomeningitis virus (LCMV)-persistent infections and demonstrated that suppression of chronic IFN-b signaling can reset the host immunity and enable contro…”
ResultBénard, A., Mittelstädt, A., Klösch, B., Glanz, K., Müller, J., Schoen, J., Nüse, B., Brunner, M., Naschberger, E., Stürzl, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112637 · Cited by 31
Thompson, L. J., Lai, J.-F., Valladao, A. C., Thelen, T. D., Urry, Z., & Ziegler, S. F. (2016) · Nature Immunology · doi:10.1038/ni.3329 · Cited by 30
CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells
O’Brien, M. P., Manches, O., Wilen, C. B., Gopal, R., Huq, R., Wu, V., Sunseri, N., & Bhardwaj, N. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005553 · Cited by 30
Dysregulation of humoral immunity in chronic infection
Cooper, L., & Good‐Jacobson, K. L. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12338 · Cited by 30
“IFN-I signaling blockade has been shown to reduce immune suppression and improve viral clearance.(65,67-69) One postulated mechanism by which IFN-I signaling becomes disruptive to the immune system during HIV infection is by inducing the loss of CD4 T cells(64) and B cells.”
BackgroundZander, R., Khatun, A., Kasmani, M. Y., Chen, Y., & Cui, W. (2022) · eLife · doi:10.7554/elife.80079 · Cited by 32
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
Chiocca, E. A., Nakashima, H., & Nguyen, T. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s66081 · Cited by 30
Teh, C. E., Preston, S., Robbins, A. K., Stutz, M. D., Cooney, J. P., Clark, M. P., Policheni, A. N., Allison, C. C., Mackiewicz, L., Arandjelovic, P., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8041 · Cited by 30
“During the first few weeks of chronic infection with LCMV, blocking IFN-I causes increases in viral loads (53).”
BackgroundRegulatory T Cells in Autoimmune and Viral Chronic Hepatitis
Lapierre, P., & Lamarre, A. (2015) · Journal of Immunology Research · doi:10.1155/2015/479703 · Cited by 31
“This is similar to the type I interferon paradox during chronic viral infections where interferon-α/β signaling can both limit early viral replication, through inhibition of viral transcription and translation and through degradation of viral nucleic acids while also suppressing immune responses later during infection…”
BackgroundKnuschke, T., Rotan, O., Bayer, W., Kollenda, S., Dickow, J., Sutter, K., Hansen, W., Dittmer, U., Lang, K. S., Epple, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00614 · Cited by 28
“While IFN I where shown to enhance T cell priming and increase the cytotoxic capacity of CD8+ T cells during viral infections (14–17), they can also foster mechanisms of immunosuppression (25, 41).”
Molecular Basis of the Differentiation and Function of Virus Specific Follicular Helper CD4+ T Cells
Huang, Q., Hu, J., Tang, J., Xu, L., & Ye, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00249 · Cited by 30
“Although we have not yet got a comprehensive understanding of the biased differentiation of Tfh cells in chronic viral infection, previous research proved that type I IFN signaling may be an important mediator involved in the shift from Th1 to Tfh cells (94) (95) (96) (97) .”
ResultComplexities of Type I Interferon Biology: Lessons from LCMV
Suprunenko, T., & Hofer, M. J. (2019) · Viruses · doi:10.3390/v11020172 · Cited by 33
“Yet, reduced virus load and enhanced viral clearance in these mice is not due to increased CD8+ cytotoxic T cell activity but is mediated by an enhanced CD4+ T cell response and IFN-γ-dependent mechanisms [9,70].”
BackgroundInfluentialA dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control
Namineni, S., O’Connor, T., Faure‐Dupuy, S., Johansen, P., Riedl, T., Liu, K., Xu, H. C., Singh, I., Shinde, P. V., Li, F., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.019 · Cited by 29
Xia, L., Wu, J., Pattaradilokrat, S., Tumas, K. C., He, X., Peng, Y., Huang, R., Myers, T. G., Long, C. A., Wang, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33599-1 · Cited by 27
Type I interferon underlies severe disease associated with Junín virus infection in mice
Hickerson, B. T., Sefing, E. J., Bailey, K. W., Wettere, A. J. V., Penichet, M. L., & Gowen, B. B. (2020) · eLife · doi:10.7554/elife.55352 · Cited by 30
“( Stifter and Feng, 2015 ), which has been shown to affect the development of an effective adaptive immune response and contributes to the inability of the host to resolve persistent LCMV infections ( Teijaro et al., 2013 ; Wilson et al., 2013 ).”
Gilroy, D. W. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00597-w · Cited by 27
Hajj, H. E., & Bazarbachi, A. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957535 · Cited by 29
Richert-Spuhler, L. E., & Lund, J. M. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.07.015 · Cited by 28
Dorhoi, A., Iannaccone, M., Maertzdorf, J., Nouailles, G., Weiner, J. M., & Kaufmann, S. H. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00036 · Cited by 29
“In support of this notion, investigations focusing on lymphocytic choriomeningitis virus (LCMV) infection describe a paradoxical detrimental role of IFN I during the chronic phase of this viral disease (45, 46).”
Innate Antiviral Defenses Independent of Inducible IFNα/β Production
Paludan, S. R. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.06.003 · Cited by 29
de Weerd, N. A., Matthews, A. Y., Pattie, P. R., Bourke, N. M., Lim, S. S., Vivian, J. P., Rossjohn, J., & Hertzog, P. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.773788 · Cited by 29
“(18), chronic viral infection (8, 19), and in the transmission of neuropathic pain (20).”
BackgroundExpression Pattern of Individual IFNA Subtypes in Chronic HIV Infection
Li, Y., Sun, B., Eßer, S., Jessen, H. K., Streeck, H., Widera, M., Yang, R., Dittmer, U., & Sutter, K. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0076 · Cited by 27
Carnathan, D. G., Lawson, B., Yu, J., Patel, K., Billingsley, J. M., Tharp, G. K., Delmas, O. M., Dawoud, R. A., Wilkinson, P. A., Nicolette, C. A., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01760-17 · Cited by 27
Cubas-Gaona, L. L., Díaz-Beneitez, E., Ciscar, M., Rodrígúez, J. F., & Rodríguez, D. (2018) · Journal of Virology · doi:10.1128/jvi.00364-18 · Cited by 31
“Human immunodeficiency virus (78), lymphocytic choriomeningitis virus (79, 80), classical swine fever virus (81), Newcastle disease virus (82), avian influenza virus (58), and SARS coronavirus (57) are representative examples of this direct relationship between the type I IFN response and the rigor of the clinical out…”
BackgroundEtiology and Pathogenesis of Systemic Lupus Erythematosus
Crow, M. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00079-6 · Cited by 31
Infectious Diseases and the Lymphoid Extracellular Matrix Remodeling: A Focus on Conduit System
Morgado, F. N., da Silva, A. V. A., & Porrozzi, R. (2020) · Cells · doi:10.3390/cells9030725 · Cited by 28
“In the presence of IFN-I, cellular exhaustion is induced through PD-L1 and IL-10 expression inhibiting the response of virus-specific CD8+ T cells and favoring virus persistence [63,64].”
BackgroundDecoding the complexity of type I interferon to treat persistent viral infections
Wilson, E. B., & Brooks, D. G. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.10.003 · Cited by 26
Self-citationType I Interferon Promotes Humoral Immunity in Viral Vector Vaccination
Zhong, C., Liu, F., Hajnik, R. L., Lei, Y., Chen, K., Wang, M., Liang, Y., Sun, J., Soong, L., Hou, W., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00925-21 · Cited by 27
In vivo effects of methamphetamine on HIV-1 replication: A population-based study
Jiang, J., Wang, M., Liang, B., Shi, Y. Y., Su, Q.-J., Chen, H., Huang, J., Su, J., Pan, P., Yu, L., et al. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.12.027 · Cited by 26
Pleiotropic Roles of Type 1 Interferons in Antiviral Immune Responses
Teijaro, J. R. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.08.001 · Cited by 29
“Importantly, blockade of IFNAR1 both prior to and following established persistent LCMV infection promoted faster virus clearance and required an intact CD4 T cell compartment (Teijaro et al., 2013; Wilson et al., 2013) .”
BackgroundType I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection
Daugan, M., Murira, A., Mindt, B. C., Germain, A., Tarrab, E., Lapierre, P., Fritz, J. H., & Lamarre, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00564 · Cited by 26
“As depicted in Figure 5A, LCMV-specific-binding Ab responses were not significantly affected by IFNAR blockade as observed in previous reports (16, 17).”
BackgroundResultInfluentialEbola Immunity: Gaining a Winning Position in Lightning Chess
Ploquin, A., Zhou, Y., & Sullivan, N. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700827 · Cited by 26
“detrimental, as observed in chronic lymphocytic choriomeningitis virus infection, in which CD8 T cell exhaustion is driven by immune activation and the upregulation of inhibitory receptors (59, 60).”
BackgroundSacramento, L. A., Benevides, L., Maruyama, S. R., Tavares, L., Fukutani, K. F., Francozo, M., Sparwasser, T. D., Cunha, F. Q., de Almeida, R. P., Silva, J. S., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008435 · Cited by 26
“Suppressive factors play a dominant role since their absence decreases the expression of IL-10 and PDL1 and promotes viral clearance in an IFN-γ-producing CD4 T-cell-dependent manner [43,69].”
BackgroundSustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity
Brunet‐Ratnasingham, E., Morin, S., Randolph, H. E., Labrecque, M., Bélair, J., Lima-Barbosa, R., Pagliuzza, A., Marchitto, L., Hultström, M., Niessl, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48556-y · Cited by 28
“Seminal studies in the murine lymphocytic chor-iomeningitis virus (LCMV) model support this hypothesis 28,39 : while IFNsarecriticalintheearlygenerationofantiviralresponses,sustained type I IFN signaling in chronic Clone 13 infection was associated with poor antibody, B cell and CD4 + T cell…”
Context-dependent impact of type I interferon signaling in cancer
Ruiz-Iglesias, A., Guilbaud, E., Galluzzi, L., & Mañes, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02495-4 · Cited by 27
“Further corroborating the notion that type I IFN signaling may de facto limit proficient immune responses in some contexts, blocking IFNAR signaling with a monoclonal antibody has been shown to improve the control of persistent lymphocytic choriomeningitis virus infection (LCMV) in mice [124, 125].”
Edwards, C. L., Best, S. E., Gun, S. Y., Claser, C., James, K. R., de, M. M., Sebina, I., Rivera, F. D. L., Amante, F. H., Hertzog, P. J., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444824 · Cited by 25
Swainson, L. A., Sharma, A., Ghneim, K., Ribeiro, S. P., Wilkinson, P. A., Dunham, R. M., Albright, R. G., Wong, S., Estes, J. D., Piatak, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153046 · Cited by 25
Kamyshnyi, O., Koval, G. D., Kobevko, O., Buchynskyi, M., Oksenych, V., Kainov, D. E., Lyubomirskaya, K., Kamyshna, I. I., Potters, G., & Moshynets, O. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086887 · Cited by 27
“At the same time, interferons can support the expansion of Th1 and Tfh in the acute phase of infection, but cause their depletion during the chronic phase [46].”
BackgroundProtective versus Pathogenic Type I Interferon Responses during Virus Infections
Jung, K. I., McKenna, S., Vijayamahantesh, V., He, Y., & Hahm, B. (2023) · Viruses · doi:10.3390/v15091916 · Cited by 29
“Intriguingly, blockade of type I IFN signaling using anti-IFNAR1 antibody during LCMV Cl 13 chronic infection relieved T cell suppression and led to accelerated clearance of viral infection [77,78].”
BackgroundHonke, N., Shaabani, N., Merches, K., Gassa, A., Kraft, A. R. M., Ehrhardt, K., Häussinger, D., Löhning, M., Dittmer, U., Hengel, H., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201545765 · Cited by 25
Price, A. A., Tedesco, D., Prasad, M. R., Workowski, K., Walker, C. M., Suthar, M. S., Honegger, J. R., & Grakoui, A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602319113 · Cited by 25
“” Indeed, in a mouse model of chronic infection, blockade of type I IFN before infection with lymphocytic choriomeningitis virus clone 13 enhanced viral load during the acute phase of infection, but led to viral clearance at later time points (23, 24).”
BackgroundTuberculosis as an unconventional interferonopathy
Vance, R. E. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102508 · Cited by 24
Shiiya, A., Noguchi, T., Tomaru, U., Ariga, S., Takashima, Y., Ohhara, Y., Taguchi, J., Takeuchi, S., Shimizu, Y., Kinoshita, I., et al. (2022) · Cancer Science · doi:10.1111/cas.15701 · Cited by 24
The Complexity of Interferon Signaling in Host Defense against Protozoan Parasite Infection
Deng, S., Graham, M. L., & Chen, X. (2023) · Pathogens · doi:10.3390/pathogens12020319 · Cited by 25
IL-27 Suppresses Antimicrobial Activity in Human Leprosy
Teles, R. M. B., Kelly‐Scumpia, K. M., Sarno, E. N., Rea, T. H., Ochoa, M. T., Cheng, G., & Modlin, R. L. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.195 · Cited by 28
“, 2013) and viral (Teijaro et al., 2013; Wilson et al., 2013) infections.”
BackgroundSelf-citationMoore, T. C., Cody, L. A., Kumm, P. M., Brown, D. M., & Petro, T. M. (2013) · Virus Research · doi:10.1016/j.virusres.2013.10.003 · Cited by 25
“These results suggest that the antiviral effects of both IL-6 and IFN-γ require IRF3 downstream of their receptors and are consistent with recent reports showing that IFNγ expression exacerbates chronic viral infections when given later during infection (Teijaro et al., 2013; Wilson et al., 2013).”
ResultTLR4 signaling improves PD-1 blockade therapy during chronic viral infection
Wang, Y., Chung, Y. R., Eitzinger, S., Palacio, N. M., Gregory, S., Bhattacharyya, M., & Penaloza‐MacMaster, P. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007583 · Cited by 25
Niche Specific Microbiota-Dependent and Independent Bone Loss around Dental Implants and Teeth
Heyman, O., Horev, Y., Koren, N., Barel, O., Aizenbud, I., Aizenbud, Y., Brandwein, M., Shapira, L., Hovav, A., & Wilensky, A. (2020) · Journal of Dental Research · doi:10.1177/0022034520920577 · Cited by 25
“, IFN-α and IFN-β), which was previously shown to induce chronic inflammation and tissue destruction (Wilson et al. 2013).”
BackgroundRiedelberger, M., Penninger, P., Tscherner, M., Hadriga, B., Brunnhofer, C., Jenull, S., Stoiber, A., Bourgeois, C., Petryshyn, A., Glaser, W., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101121 · Cited by 23
Metadata
- Authors
- Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G.
- Affiliations
- University of California, Los Angeles (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Brooks, David G.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 202-207
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3704950
- OpenAlex
- W2049868800
- Cited by
- 709
- References
- 29
- Citations by year
- 2026: 26 · 2025: 37 · 2024: 34 · 2023: 35 · 2022: 35 · 2021: 48 · 2020: 50 · 2019: 50 · 2018: 58 · 2017: 72 · 2016: 87 · 2015: 72 · 2014: 70 · 2013: 34
- FWCI
- 48.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000077)
- National Heart, Lung, and Blood Institute (R01HL108949, HL108949)
- National Institute of Allergy and Infectious Diseases (AI060567, T32AI060567, U01AI082975, R01AI085043, AI082975, R01AI056154, AI085043, R01AI047868, P30AI028697)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR063020)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- type I interferon signaling, chronic infection, lymphocytic choriomeningitis virus, viral persistence, immune activation, immunosuppression, CD4+ T cells, interferon-gamma, antiviral immunity, viral clearance
- MeSH terms
- Animals, Antibodies, Arenaviridae Infections, Dendritic Cells, Immune Tolerance, Interferon Type I, Interferon-gamma, Lymphocytic choriomeningitis virus, Virus Replication, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.